Literature DB >> 17611398

P21 gene knock down does not identify genetic effectors seen with gene knock out.

Bedri Karakas1, Ashani T Weeraratna, Abde M Abukhdeir, Hiroyuki Konishi, John P Gustin, Michele I Vitolo, Kurtis E Bachman, Ben Ho Park.   

Abstract

RNA interference (RNAi) has become a popular tool for analyzing gene function in cancer research. The feasibility of using RNAi in cellular and animal models as an alternative to conventional gene knock out approaches has been demonstrated. Although these studies show that RNAi can recapitulate phenotypes seen in knock out animals and their derived cell lines, a systematic study rigorously comparing downstream effector genes between RNAi and gene knock out has not been performed. Here we present data contrasting the phenotypic and genotypic changes that occur with either stable knock down via RNAi of the cyclin dependent kinase inhibitor p21 versus its somatic cell knock out counterpart in the human mammary epithelial cell line MCF-10A. Our results demonstrate that p21 knock down clones display a growth proliferative response upon exposure to Transforming Growth Factor-Beta Type 1 (TGFbeta) similar to p21 knock out clones. However, gene expression profiles were significantly different in p21 knock down cells versus p21 knock out clones. Importantly p21 knock down clones did not display increased gene expression of interleukin-1alpha (IL-1alpha), a critical effector of this growth response previously validated in p21 knock out cells. We conclude that gene knock out can yield additional vital information that may be missed with gene knock down strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611398      PMCID: PMC2667557          DOI: 10.4161/cbt.6.7.4202

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  26 in total

1.  Prevalence of off-target effects in Drosophila RNA interference screens.

Authors:  Yong Ma; Adrian Creanga; Lawrence Lum; Philip A Beachy
Journal:  Nature       Date:  2006-09-10       Impact factor: 49.962

Review 2.  Enhancing and confirming the specificity of RNAi experiments.

Authors:  Bryan R Cullen
Journal:  Nat Methods       Date:  2006-09       Impact factor: 28.547

Review 3.  On the art of identifying effective and specific siRNAs.

Authors:  Yi Pei; Thomas Tuschl
Journal:  Nat Methods       Date:  2006-09       Impact factor: 28.547

4.  Minimizing the risk of reporting false positives in large-scale RNAi screens.

Authors:  Christophe J Echeverri; Philip A Beachy; Buzz Baum; Michael Boutros; Frank Buchholz; Sumit K Chanda; Julian Downward; Jan Ellenberg; Andrew G Fraser; Nir Hacohen; William C Hahn; Aimee L Jackson; Amy Kiger; Peter S Linsley; Lawrence Lum; Yong Ma; Bernard Mathey-Prévôt; David E Root; David M Sabatini; Jussi Taipale; Norbert Perrimon; René Bernards
Journal:  Nat Methods       Date:  2006-10       Impact factor: 28.547

5.  Evidence of off-target effects associated with long dsRNAs in Drosophila melanogaster cell-based assays.

Authors:  Meghana M Kulkarni; Matthew Booker; Serena J Silver; Adam Friedman; Pengyu Hong; Norbert Perrimon; Bernard Mathey-Prevot
Journal:  Nat Methods       Date:  2006-10       Impact factor: 28.547

6.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

7.  Persistent mismatch repair deficiency following targeted correction of hMLH1.

Authors:  M B Weiss; M I Vitolo; K Baerenfaller; G Marra; B H Park; K E Bachman
Journal:  Cancer Gene Ther       Date:  2006-11-03       Impact factor: 5.987

8.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer.

Authors:  Dae-Sung Yoon; Robert P Wersto; Weibo Zhou; Francis J Chrest; Elizabeth S Garrett; Teag Kyu Kwon; Edward Gabrielson
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.

Authors:  Marie-France Robert; Steves Morin; Normand Beaulieu; France Gauthier; Ian C Chute; Annie Barsalou; A Robert MacLeod
Journal:  Nat Genet       Date:  2002-12-23       Impact factor: 38.330

10.  Systematic functional analysis of the Caenorhabditis elegans genome using RNAi.

Authors:  Ravi S Kamath; Andrew G Fraser; Yan Dong; Gino Poulin; Richard Durbin; Monica Gotta; Alexander Kanapin; Nathalie Le Bot; Sergio Moreno; Marc Sohrmann; David P Welchman; Peder Zipperlen; Julie Ahringer
Journal:  Nature       Date:  2003-01-16       Impact factor: 49.962

View more
  17 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

2.  Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil.

Authors:  Dennis R Harris; Alexandra Mims; Fred Bunz
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

3.  Knockout of the Ribonuclease Inhibitor Gene Leaves Human Cells Vulnerable to Secretory Ribonucleases.

Authors:  Sydney P Thomas; Eunji Kim; Jin-Soo Kim; Ronald T Raines
Journal:  Biochemistry       Date:  2016-11-08       Impact factor: 3.162

4.  The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Authors:  Josh Lauring; Abde M Abukhdeir; Hiroyuki Konishi; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

5.  The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Authors:  Joseph P Garay; Bedri Karakas; Abde M Abukhdeir; David P Cosgrove; John P Gustin; Michaela J Higgins; Hiroyuki Konishi; Yuko Konishi; Josh Lauring; Morassa Mohseni; Grace M Wang; Danijela Jelovac; Ashani Weeraratna; Cheryl A Sherman Baust; Patrice J Morin; Antoun Toubaji; Alan Meeker; Angelo M De Marzo; Gloria Lewis; Andrea Subhawong; Pedram Argani; Ben H Park
Journal:  Breast Cancer Res       Date:  2012-02-09       Impact factor: 6.466

6.  Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.

Authors:  Santhi Achuthan; Thankayyan R Santhoshkumar; Jem Prabhakar; S Asha Nair; M Radhakrishna Pillai
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

7.  EAPP: gatekeeper at the crossroad of apoptosis and p21-mediated cell-cycle arrest.

Authors:  P Andorfer; H Rotheneder
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

8.  Combined shRNA over CRISPR/cas9 as a methodology to detect off-target effects and a potential compensatory mechanism.

Authors:  Liat Peretz; Elazar Besser; Renana Hajbi; Natania Casden; Dan Ziv; Nechama Kronenberg; Liat Ben Gigi; Sahar Sweetat; Saleh Khawaled; Rami Aqeilan; Oded Behar
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

9.  GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers.

Authors:  John P Gustin; Jernelle Miller; Mina Farag; D Marc Rosen; Matthew Thomas; Robert B Scharpf; Josh Lauring
Journal:  Oncotarget       Date:  2017-10-20

10.  Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.

Authors:  Justin Cidado; Hong Yuen Wong; D Marc Rosen; Ashley Cimino-Mathews; Joseph P Garay; Abigail G Fessler; Zeshaan A Rasheed; Jessica Hicks; Rory L Cochran; Sarah Croessmann; Daniel J Zabransky; Morassa Mohseni; Julia A Beaver; David Chu; Karen Cravero; Eric S Christenson; Arielle Medford; Austin Mattox; Angelo M De Marzo; Pedram Argani; Ajay Chawla; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.